Amgen Inc. (AMGN) Shares Bought by ClariVest Asset Management LLC
ClariVest Asset Management LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 14.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 386,472 shares of the medical research company’s stock after buying an additional 48,271 shares during the period. Amgen accounts for 1.8% of ClariVest Asset Management LLC’s investment portfolio, making the stock its 8th largest position. ClariVest Asset Management LLC’s holdings in Amgen were worth $58,802,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Oakworth Capital Inc. increased its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN increased its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock valued at $155,000 after buying an additional 85 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock valued at $164,000 after buying an additional 6 shares during the period. Vigilant Capital Management LLC increased its stake in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock valued at $195,000 after buying an additional 33 shares during the period. Finally, Calamos Wealth Management LLC bought a new stake in shares of Amgen during the second quarter valued at about $202,000. Institutional investors and hedge funds own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 1.45% during trading on Friday, hitting $161.90. 2,817,469 shares of the stock traded hands. The company has a 50 day moving average price of $169.59 and a 200 day moving average price of $162.28. Amgen Inc. has a 12 month low of $139.02 and a 12 month high of $176.85. The firm has a market cap of $121.16 billion, a price-to-earnings ratio of 16.57 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.57 EPS. Analysts anticipate that Amgen Inc. will post $11.35 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Investors of record on Wednesday, November 16th will be issued a dividend of $1.00 per share. This represents a $4.00 annualized dividend and a dividend yield of 2.47%. Amgen’s dividend payout ratio is currently 40.90%.
AMGN has been the topic of several recent research reports. Jefferies Group raised their target price on shares of Amgen from $187.00 to $198.00 and gave the stock a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price on the stock in a report on Wednesday, June 29th. Citigroup Inc. lowered their target price on shares of Amgen from $175.00 to $172.00 and set a “neutral” rating on the stock in a report on Wednesday, September 28th. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Finally, Argus reaffirmed a “buy” rating and set a $195.00 target price (up from $185.00) on shares of Amgen in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $184.94.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.